Dimethyl fumarate Polpharma

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
22-12-2023
Summary of Product characteristics Summary of Product characteristics (SPC)
22-12-2023
Public Assessment Report Public Assessment Report (PAR)
22-12-2023

Active ingredient:

dimethyl fumarate

Available from:

Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

ATC code:

L04AX07

INN (International Name):

dimethyl fumarate

Therapeutic group:

Immunosuppressants

Therapeutic area:

Multiple Sclerosis, Relapsing-Remitting

Therapeutic indications:

Dimethyl fumarate Polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Product summary:

Revision: 4

Authorization status:

Authorised

Authorization date:

2022-05-13

Patient Information leaflet

                                30
B.
PACKAGE LEAFLET
ema-combined-h-5955-en
Pg. 30
Medicinal product no longer authorised
31
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
DIMETHYL FUMARATE POLPHARMA 120 MG GASTRO-RESISTANT CAPSULES, HARD
DIMETHYL FUMARATE POLPHARMA 240 MG GASTRO-RESISTANT CAPSULES, HARD
_Dimethyl fumarate _
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Dimethyl fumarate Polpharma is and what it is used for
2.
What you need to know before you take Dimethyl fumarate Polpharma
3.
How to take Dimethyl fumarate Polpharma
4.
Possible side effects
5.
How to store Dimethyl fumarate Polpharma
6.
Contents of the pack and other information
1.
WHAT DIMETHYL FUMARATE POLPHARMA IS AND WHAT IT IS USED FOR
WHAT DIMETHYL FUMARATE POLPHARMA IS
Dimethyl fumarate Polpharma is a medicine that contains the active
substance
DIMETHYL FUMARATE
.
WHAT DIMETHYL FUMARATE POLPHARMA IS USED FOR
DIMETHYL FUMARATE POLPHARMA IS USED TO TREAT RELAPSING-REMITTING
MULTIPLE SCLEROSIS (MS) IN
PATIENTS AGED 13 YEARS AND OLDER.
MS is a long-term condition that affects the central nervous system
(CNS), including the brain and
the spinal cord. Relapsing-remitting MS is characterised by repeated
attacks (relapses) of nervous
system symptoms. Symptoms vary from patient to patient, but typically
include walking difficulties,
feeling off balance and visual difficulties (e.g. blurred or double
vision). These symptoms may
disappear completely when the relapse is over, but some problems may
remain.
HOW DIMETHYL FUMARATE POLPHARMA WORKS
Dimethyl fum
                                
                                Read the complete document

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
ema-combined-h-5955-en
Pg. 1
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Dimethyl fumarate Polpharma 120 mg gastro-resistant capsules, hard
Dimethyl fumarate Polpharma 240 mg gastro-resistant capsules, hard
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Dimethyl fumarate Polpharma 120 mg:
Each capsule contains 120 mg dimethyl fumarate.
Dimethyl fumarate Polpharma 240 mg:
Each capsule contains 240 mg dimethyl fumarate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Gastro-resistant hard capsule
Dimethyl fumarate Polpharma 120 mg: hard gelatin capsules, length: 19
mm, with white body and
light-green cap, with overprint on the body 120 mg.
Dimethyl fumarate Polpharma 240 mg: hard gelatin capsules, length: 23
mm, light-green, with
overprint on the body 240 mg.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Dimethyl fumarate Polpharma is indicated for the treatment of adult
and paediatric patients aged 13
years and older with relapsing remitting multiple sclerosis (RRMS).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment should be initiated under supervision of a physician
experienced in the treatment of
multiple sclerosis.
Posology
The starting dose is 120 mg twice a day. After 7 days, the dose should
be increased to the
recommended maintenance dose of 240 mg twice a day (see section 4.4).
If a patient misses a dose, a double dose should not be taken. The
patient may take the missed dose
only if they leave 4 hours between doses. Otherwise the patient should
wait until the next scheduled
dose.
Temporary dose reduction to 120 mg twice a day may reduce the
occurrence of flushing and
gastrointestinal adverse reactions. Within 1 month, the recommended
maintenance dose of 240 mg
twice a day should be resumed.
ema-combined-h-5955-en
Pg. 2
Medicinal product no longer authorised
3
Dimethyl fumarate Polpharma should be taken with food (see section
5.2). For those patients who may
experience flushing or gastrointestinal adve
                                
                                Read the complete document

Similar products

Active ingredient dimethyl fumarate

dimethyl fumarate

ATC code L04AX07

L04AX07

Marketed by Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

INN (International Name) dimethyl fumarate

dimethyl fumarate

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 22-12-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 22-12-2023
Public Assessment Report Public Assessment Report Bulgarian 22-12-2023
Patient Information leaflet Patient Information leaflet Spanish 22-12-2023
Summary of Product characteristics Summary of Product characteristics Spanish 22-12-2023
Public Assessment Report Public Assessment Report Spanish 22-12-2023
Patient Information leaflet Patient Information leaflet Czech 22-12-2023
Summary of Product characteristics Summary of Product characteristics Czech 22-12-2023
Public Assessment Report Public Assessment Report Czech 22-12-2023
Patient Information leaflet Patient Information leaflet Danish 22-12-2023
Summary of Product characteristics Summary of Product characteristics Danish 22-12-2023
Public Assessment Report Public Assessment Report Danish 22-12-2023
Patient Information leaflet Patient Information leaflet German 22-12-2023
Summary of Product characteristics Summary of Product characteristics German 22-12-2023
Public Assessment Report Public Assessment Report German 22-12-2023
Patient Information leaflet Patient Information leaflet Estonian 22-12-2023
Summary of Product characteristics Summary of Product characteristics Estonian 22-12-2023
Public Assessment Report Public Assessment Report Estonian 22-12-2023
Patient Information leaflet Patient Information leaflet Greek 22-12-2023
Summary of Product characteristics Summary of Product characteristics Greek 22-12-2023
Public Assessment Report Public Assessment Report Greek 22-12-2023
Patient Information leaflet Patient Information leaflet French 22-12-2023
Summary of Product characteristics Summary of Product characteristics French 22-12-2023
Public Assessment Report Public Assessment Report French 22-12-2023
Patient Information leaflet Patient Information leaflet Italian 22-12-2023
Summary of Product characteristics Summary of Product characteristics Italian 22-12-2023
Public Assessment Report Public Assessment Report Italian 22-12-2023
Patient Information leaflet Patient Information leaflet Latvian 22-12-2023
Summary of Product characteristics Summary of Product characteristics Latvian 22-12-2023
Public Assessment Report Public Assessment Report Latvian 22-12-2023
Patient Information leaflet Patient Information leaflet Lithuanian 22-12-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 22-12-2023
Public Assessment Report Public Assessment Report Lithuanian 22-12-2023
Patient Information leaflet Patient Information leaflet Hungarian 22-12-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 22-12-2023
Public Assessment Report Public Assessment Report Hungarian 22-12-2023
Patient Information leaflet Patient Information leaflet Maltese 22-12-2023
Summary of Product characteristics Summary of Product characteristics Maltese 22-12-2023
Public Assessment Report Public Assessment Report Maltese 22-12-2023
Patient Information leaflet Patient Information leaflet Dutch 22-12-2023
Summary of Product characteristics Summary of Product characteristics Dutch 22-12-2023
Public Assessment Report Public Assessment Report Dutch 22-12-2023
Patient Information leaflet Patient Information leaflet Polish 22-12-2023
Summary of Product characteristics Summary of Product characteristics Polish 22-12-2023
Public Assessment Report Public Assessment Report Polish 22-12-2023
Patient Information leaflet Patient Information leaflet Portuguese 22-12-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 22-12-2023
Public Assessment Report Public Assessment Report Portuguese 22-12-2023
Patient Information leaflet Patient Information leaflet Romanian 22-12-2023
Summary of Product characteristics Summary of Product characteristics Romanian 22-12-2023
Public Assessment Report Public Assessment Report Romanian 22-12-2023
Patient Information leaflet Patient Information leaflet Slovak 22-12-2023
Summary of Product characteristics Summary of Product characteristics Slovak 22-12-2023
Public Assessment Report Public Assessment Report Slovak 22-12-2023
Patient Information leaflet Patient Information leaflet Slovenian 22-12-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 22-12-2023
Public Assessment Report Public Assessment Report Slovenian 22-12-2023
Patient Information leaflet Patient Information leaflet Finnish 22-12-2023
Summary of Product characteristics Summary of Product characteristics Finnish 22-12-2023
Public Assessment Report Public Assessment Report Finnish 22-12-2023
Patient Information leaflet Patient Information leaflet Swedish 22-12-2023
Summary of Product characteristics Summary of Product characteristics Swedish 22-12-2023
Public Assessment Report Public Assessment Report Swedish 22-12-2023
Patient Information leaflet Patient Information leaflet Norwegian 22-12-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 22-12-2023
Patient Information leaflet Patient Information leaflet Icelandic 22-12-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 22-12-2023
Patient Information leaflet Patient Information leaflet Croatian 22-12-2023
Summary of Product characteristics Summary of Product characteristics Croatian 22-12-2023
Public Assessment Report Public Assessment Report Croatian 22-12-2023

Search alerts related to this product

Alerts Dimethyl fumarate Polpharma

Dimethyl fumarate Polpharma

View documents history

Documents history Documents history

Dimethyl fumarate Polpharma